{
    "Trade/Device Name(s)": [
        "Avie A1C Test System",
        "AvieTM A1C Test System",
        "AvieTM Alc Test System"
    ],
    "Submitter Information": "MEC Dynamics Corporation",
    "510(k) Number": "K081269",
    "Predicate Device Reference 510(k) Number(s)": [
        "K041635",
        "K051321"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "LCP"
    ],
    "Summary Letter Date": "February 24, 2009",
    "Summary Letter Received Date": "February 25, 2009",
    "Submission Date": "",
    "Regulation Number(s)": [
        "21CFR864.7470"
    ],
    "Regulation Name(s)": [
        "Glycosylated hemoglobin assay"
    ],
    "Analyte Class(es)": [
        "chemistry"
    ],
    "Analyte(s)": [
        "Glycated hemoglobin (HbA1c)"
    ],
    "Specimen Type(s)": [
        "Whole blood",
        "Capillary whole blood",
        "Venous whole blood"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "Avie A1C Test System Reader"
    ],
    "Method(s)/Technology(ies)": [
        "Immunoassay"
    ],
    "Methodologies": [
        "Immunoassay",
        "Photometric detection (transmission)"
    ],
    "Submission Type(s)": [
        "System",
        "Analyzer",
        "Cartridge",
        "Diluent",
        "Reagent",
        "Control"
    ],
    "Document Summary": "FDA 510(k) summary for Avie A1C Test System, an immunoassay-based point-of-care analyzer for quantitative HbA1c measurement.",
    "Indications for Use Summary": "For prescription and physician-directed home use to quantitatively measure %A1C (glycated hemoglobin) in capillary or venous whole blood to monitor glycemic control in people with diabetes mellitus; not for use in patients with hemoglobinopathies HbF, HbC, and HbD.",
    "fda_folder": "Hematology"
}